Novel agents for the treatment of HIV-2 infection.
Many of the antiretrovirals used against HIV-1 are either ineffective or less effective in HIV-2 infection. There is in vitro evidence of the potency of maraviroc and several investigational agents against HIV-2. We conclude that, whilst specific boosted protease inhibitors combined with nucleoside analogues should still be considered the mainstays of HIV-2 treatment, maraviroc, T-1249, TAK-779 and AMD3100, as well as raltegravir, could contribute to regimens for treatment-experienced individuals. Factors bearing on the use and timing of these alternative agents are discussed.
Institute for Tropical Medicine, Antwerp, Belgium. kpeterson@itg.be
Kevin
K
Peterson
Sarah
S
Rowland-Jones
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000494:pharmacology*; D000077560:Enfuvirtide; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000494:pharmacology*; D023581:HIV Fusion Inhibitors / Q000494:pharmacology*; D015498:HIV-2 / Q000187:drug effects*; D006801:Humans; D008297:Male; D000077592:Maraviroc; D010446:Peptide Fragments / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology*
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D014230:Triazoles; D000077560:Enfuvirtide; D000077592:Maraviroc